摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,4-二甲基-1H-咪唑-5-甲酰胺 | 124709-80-4

中文名称
2,4-二甲基-1H-咪唑-5-甲酰胺
中文别名
——
英文名称
2,5-dimethyl-1(3)H-imidazole-4-carboxylic acid amide
英文别名
2,5-Dimethyl-1(3)H-imidazol-4-carbonsaeure-amid;2,4-Dimethyl-1H-imidazole-5-carboxamide;2,5-dimethyl-1H-imidazole-4-carboxamide
2,4-二甲基-1H-咪唑-5-甲酰胺化学式
CAS
124709-80-4
化学式
C6H9N3O
mdl
MFCD18808649
分子量
139.157
InChiKey
MUINFCUJBRRPGO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.1
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.333
  • 拓扑面积:
    71.8
  • 氢给体数:
    2
  • 氢受体数:
    2

SDS

SDS:6bb80d4916034d0b59a5125a6b611fe3
查看

反应信息

点击查看最新优质反应信息

文献信息

  • Nitro compounds, process for preparation thereof and use thereof
    申请人:Fujisawa Pharmaceutical Co., Ltd.
    公开号:US05495023A1
    公开(公告)日:1996-02-27
    A new nitro compound of the formula: ##STR1## wherein R.sup.1 and R.sup.2 are each lower alkyl or lower alkoxy(lower)alkyl, or ##STR2## is cyclized to form ##STR3## X is --O--, --S-- or --NH--, m is an integer 0 or 1, and R.sup.3 is carbamoyl, lower alkylcarbamoyl, lower alkanoyl, di-lower alkylaminosulfonyl, lower alkylsulfonyl, oxamoyl or a group of the formula: --(Y).sub.n --R.sup.4 wherein Y is --CO--, --SO.sub.2 --, --COCH.sub.2 -- or ##STR4## n is an integer of 0 or 1, and R.sup.4 is heterocyclic group which is optionally substituted with one or more substituents selected from lower alkyl, lower alkoxy, phenyl, carbamoyl, halogen, amino, lower alkylthio, hydroxy, lower alkylsulfonylamino and carbamoylmethyl, and pharmaceutically acceptable salt thereof, which are useful as vasodilators.
    一种新的硝基化合物化学式为:##STR1## 其中R.sup.1和R.sup.2分别为低烷基或低烷氧基(低)烷基,或##STR2##环化形成##STR3## X为--O--,--S--或--NH--,m为0或1的整数,R.sup.3为基甲酰基,低烷基基甲酰基,低烷酰基,二低烷基磺酰基,低烷基磺酰基,草酰基或式为--(Y).sub.n --R.sup.4的基团,其中Y为--CO--,--SO.sub.2--,--COCH.sub.2--或##STR4## n为0或1的整数,R.sup.4为杂环基,可选地取代由一个或多个取代基选自低烷基,低烷氧基,苯基,基,低烷基,羟基,低烷基磺酰基和基甲酰甲基,以及其药学上可接受的盐,其作为血管扩张剂是有用的。
  • OXAZOLE TYROSINE KINASE INHIBITORS
    申请人:Reader John Charles
    公开号:US20100298301A1
    公开(公告)日:2010-11-25
    The invention provides a compound which is an amide of the formula (1), or a salt, solvate, N-oxide or tautomer thereof; wherein: a is 0 or 1; b is 0 or 1: provided that the sum of a and b is 0 or 1; T is O or NH Ar 1 is a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S, and being optionally substituted by one or more substituents R 1 ; Ar 2 Js a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S and being optionally substituted by one or more substituents R 2 ; and R 1 and R 2 are as defined in the claims. The compounds are inhibitors of kinases and in particular FLT3, FLT4 and Aurora kinases.
    本发明提供了化合物,其为式(1)的酰胺,或其盐、溶剂合物、N-氧化物或互变异构体;其中:a为0或1;b为0或1:前提是a和b的总和为0或1;T为O或NH;Ar1为单环或双环的5-至10-成员的芳基或杂芳基,含有最多4个从O、N和S中选出的杂原子,并且可以被一个或多个取代基R1取代;Ar2为单环或双环的5-至10-成员的芳基或杂芳基,含有最多4个从O、N和S中选出的杂原子,并且可以被一个或多个取代基R2取代;R1和R2如权利要求所定义。这些化合物是激酶抑制剂,特别是FLT3、FLT4和Aurora激酶抑制剂
  • TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
    申请人:Shanghai Jemincare Pharmaceuticals Co., Ltd.
    公开号:EP3998263A1
    公开(公告)日:2022-05-18
    A compound represented by formula (I), an optical isomer thereof and a pharmaceutically acceptable salt thereof, as well as an application of said compound as an FXIa inhibitor.
    化合物(I)及其光学异构体和药学上可接受的盐,以及该化合物作为FXIa抑制剂的应用。
  • Tricyclic compound, preparation method therefor and use thereof
    申请人:SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD.
    公开号:US11518766B2
    公开(公告)日:2022-12-06
    A compound represented by formula (I), an optical isomer thereof and a pharmaceutically acceptable salt thereof, as well as an application of said compound as an FXIa inhibitor.
    一种由式(I)代表的化合物、其光学异构体和其药学上可接受的盐,以及所述化合物作为 FXIa 抑制剂的应用。
  • US8378095B2
    申请人:——
    公开号:US8378095B2
    公开(公告)日:2013-02-19
查看更多